Glooko, Novo Nordisk team up for connected insulin pens

Glooko, Novo NordiskGlooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution.

Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able to sync data from Novo Nordisk’s connected pens, according to Glooko.

Get the full story at our sister site, Drug Delivery Business News.

The post Glooko, Novo Nordisk team up for connected insulin pens appeared first on MassDevice.

Dexcom wins Health Canada nod for G6 CGM

Dexcom G6Dexcom (NSDQ:DXCM) said last week that it won Health Canada approval for its G6 continuous glucose monitoring system for people with diabetes ages two and up.

The company plans to kick off the G6 commercial launch later this year.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom wins Health Canada nod for G6 CGM appeared first on MassDevice.

Dexcom beats The Street with Q4, FY18 results

 (NSDQ:DXCM) topped expectations on Wall Street this week with its fourth quarter and full-year financial results.

The San Diego, Calif.-based company posted a net loss of -$179.7 million, or -$2.03 per share, on sales of $338 million for the 3 months ended Dec. 31, for sales growth of 52.9% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom beats The Street with Q4, FY18 results appeared first on MassDevice.

Dexcom Q4 prelims top consensus | Wall Street Beat

Wall Street beat, financial results (NSDQ:DXCM)  topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results.

The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom Q4 prelims top consensus | Wall Street Beat appeared first on MassDevice.

Dexcom completes $850m debt offering

Dexcom updated logo (NSDQ:DXCM) said that it completed the sale of $850 million of 0.75% convertible senior notes due 2023.

The San Diego, Calif.-based company expects to reel in roughly $836 million in net proceeds from the offering.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom completes $850m debt offering appeared first on MassDevice.

Diabeloop wins CE Mark for hybrid closed-loop diabetes management system

Diabeloop logo - largeDiabeloop won CE Mark clearance in the European Union this month for its hybrid closed-loop diabetes management system, DBLG1.

The Paris-based company hopes to launch its “artificial pancreas” system for adults with Type I diabetes in Europe by the second quarter in 2019.

Get the full story at our sister site, Drug Delivery Business News.

The post Diabeloop wins CE Mark for hybrid closed-loop diabetes management system appeared first on MassDevice.

DexCom prices $750m debt offering

Dexcom (NSDQ:DXCM) today priced its $750 million offering of convertible senior notes due 2023 which is slated to be offered to qualified institutional buyers.

The San Diego, Calif.-based company said that it will also offer a 13-day option to buy up to an additional $100 million aggregate principal amount of notes to purchasers in the offering.

Read the whole story on our sister site, Drug Delivery Business News

The post DexCom prices $750m debt offering appeared first on MassDevice.

Dexcom readies $750m debt offering

Dexcom G6 (NSDQ:DXCM) said yesterday that it plans to offer $750 million in convertible senior notes due 2023 in a private placement to institutional buyers.

The San Diego, Calif.-based company also expects to give buyers a 13-day option to buy up to an additional $100 million aggregate principal amount of notes.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom readies $750m debt offering appeared first on MassDevice.

10 of the best performing medical device stocks of 2018

(Image from Unsplash)

Nearly half of the world’s 100 largest medical device companies saw their stock prices increase by double-digit percentages during the first 10 months of 2018, according to a Medical Design & Outsourcing analysis.

The feat is even more amazing considering that October was a rocky month for the Dow Jones Industrial Average, with the year’s gains mostly erased amid worries over Federal Reserve interest rate hikes and the U.S.-China trade war.

Medical device companies were able to buck the trend thanks to a number of different factors, including strong product launches, positive clinical trial results, new markets opening up or internal changes.

Being innovative mattered, too. It’s not too surprising that some medical device companies spending a large amount on R&D compared to revenue – including Dexcom, Abiomed, Atricure, Edwards Lifesciences and Insulet – saw their stock prices skyrocket as they marketed innovative devices in fields including diabetes management and cardiology.

Here are 10 of 2018’s top performers and a bit about what each has accomplished so far this year.

Next>>

Managing editor Chris Newmarker contributed to this report. 

The post 10 of the best performing medical device stocks of 2018 appeared first on MassDevice.

Dexcom inks $250m amended deal with Verily for next-gen diabetes tech

 (NSDQ:DXCM) said yesterday that it plans to pay $250 million upfront in stock to Verily in an amended collaboration and licensing deal.

The two companies are working to develop a second-generation continuous glucose monitoring system. The updated deal also notes that the companies could collaborate on additional products and software.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom inks $250m amended deal with Verily for next-gen diabetes tech appeared first on MassDevice.